Phase 2 validation of AFP, DCP and AFP-L3 in early stage hepatocellular carcinoma

被引：0
|
作者：
Marrero, Jorge A.
Llovet, Josep M.
Nguyen, Mindie
Befeler, Alex
Roberts, Lewis R.
Reddy, Rajender R.
Harnois, Denise
Normolle, Daniel
Hui, Ying
Dalhgren, Jackie
Chia, David
Lok, Anna S.
Wagner, Paul D.
Feng, Ziding
Schwartz, Myron
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Mt Sinai Univ, New York, NY USA
[3] Stanford Univ, Palo Alto, CA 94304 USA
[4] Mayo Clin, Rochester, MN USA
[5] Univ Penn, Mayo Clin, Jacksonville, FL USA
[6] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[7] NCI, Bethesda, MD 20892 USA
来源：
CANCER BIOMARKERS | 2008年 / 4卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：183 / 183
页数：1
相关论文
共 50 条
  • [31] Biomarkers AFP in Combination with AFP-l3 and DCP Predicts Tumor Progression in Treatment Native HCC Patients
    Nunez, K.
    Sandow, T.
    Thevenot, P.
    Cohen, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 492 - 493
  • [32] HIGHER SENSITIVITY IN THE DIAGNOSIS OF THE HEPATOCELLULAR CARCINOMA BY ADDITIONAL MEASUREMENT OF LENS CULINARIS AGGLUTININ-REACTIVE AFP (AFP-L3)AND DES-GAMMA-CARBOXYPROTHROMBIN (DCP)
    Ertle, Judith M.
    Wichert, Marc
    Kueper, Robert
    Gerken, Guido
    Hilgard, Philip
    Conbay, Ali
    Schlaak, Joerg F.
    HEPATOLOGY, 2009, 50 (04) : 1100A - 1101A
  • [33] Biomarkers AFP in combination with AFP-L3 and DCP predicts tumor progression in treatment naive HCC patients
    Nunez, K.
    Sandow, T.
    Thevenot, P.
    Cohen, A.
    TRANSPLANTATION, 2021, 105 (08) : 78 - 79
  • [34] AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: Results of a prospective study
    Mehta, Neil
    Kotwani, Prashant
    Norman, Joshua
    Shui, Amy
    Li, Po-Yi
    Saxena, Varun
    Chan, Wesley
    Yao, Francis Y.
    LIVER TRANSPLANTATION, 2023, 29 (10) : 1041 - 1049
  • [35] The Diagnostic Performance of AFP, AFP-L3, DCP, CA199, and Their Combination for Primary Liver Cancer
    Liu, Yue
    Jiang, Wenrong
    Li, Xiangxiao
    Zhao, Hu
    Wang, Shiwen
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2025, 12 : 513 - 526
  • [36] The diagnostic value of PIVKA-II, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma
    Qi, Famei
    Zhou, Aihua
    Yan, Li
    Yuan, Xiumei
    Wang, Danni
    Chang, Ruoyun
    Zhang, Yujun
    Shi, Funa
    Han, Xiaomei
    Hou, Jinxia
    Wei, Lianhua
    Zhang, Xu
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2020, 34 (05)
  • [37] AFP-L3 and DCP tumor markers strongly predict early hepatocellular carcinoma recurrence after liver transplantation and should be an LT exclusion criterion
    Norman, J.
    Kotwani, P.
    Yao, F.
    Mehta, N.
    TRANSPLANTATION, 2022, 106 (8S) : 71 - 72
  • [38] Development and clinical evaluation of AFP-L3% as a new tumor marker for hepatocellular carcinoma
    Wang, YY
    Kanke, F
    Kato, H
    Wise, MG
    Mallory, TS
    Satomura, S
    CLINICAL CHEMISTRY, 2005, 51 : A58 - A58
  • [39] AFP、DCP和AFP-L3%联合检测对肝细胞肝癌的诊断价值
    张明跃
    陈浩
    癌症进展, 2019, 17 (06) : 719 - 721
  • [40] DCP and AFP-L3 Are Complementary to AFP in Predicting High-Risk Explant Features: Results of a Prospective Study
    Kotwani, Prashant
    Chan, Wesley
    Yao, Francis
    Mehta, Neil
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (03) : 701 - +
12345